Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Inmune Bio Inc (INMB)
NASDAQ:INMB
Inmune Bio (INMB) Stock Price & Analysis
284 Followers
INMB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.50 - $14.74
Previous Close$8.08
Volume85.69K
Average Volume (3M)160.16K
Market Cap
$159.84M
Enterprise Value$134.43M
Total Cash (Recent Filing)$35.85M
Total Debt (Recent Filing)$10.44M
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Aug 06, 2024EPS Estimate
-$0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.92
Shares Outstanding19,782,429
10 Day Avg. Volume127,915
30 Day Avg. Volume160,161
Standard Deviation0.27
R-Squared0.13
Alpha0.00415
Financial Highlights & Ratios
Price to Book (P/B)6.78
Price to Sales (P/S)945.73
Price to Cash Flow (P/CF)-10.80
P/FCF Ratio0.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue867.30
Enterprise Value/Gross Profit867.30
Enterprise Value/Ebitda0.24
Forecast
1Y Price Target
$19.67Price Target Upside130.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Inmune Bio News
PremiumCompany Announcements
Inmune Bio Grants CEO Stock Options Under Incentive Plan
PremiumPress Releases
INmune Bio Inc. to Join Russell 3000® Index
PremiumCompany Announcements
Inmune Bio Inc Grants Stock Options to Top Executives
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPhase 2 trial of XPro in early Alzheimer's disease remains on track to complete full enrollment, with results expected soon after.
Financial StabilityINmune has sufficient cash to fund operations into 2025, following successful fundraising through equity offerings.
Therapeutic PotentialThe INKmune program's potential expansion into renal cell cancer could open new therapeutic avenues and market opportunities.
Bears Say
Clinical TrialsThe company has closed enrollment in the open label extension study, which might be seen as a missed opportunity for additional data.
Financial PerformanceINmune filed its 10-K, reporting YE23 results with a net loss of ($30M).
Treatment EfficacyHistorically, mCRPC has been challenging to treat with IO reactivity, with many treatments showing promise in animal models but failing in larger studies.
---
Ownership Overview
36.82% Insiders
3.45% Mutual Funds
5.92% Other Institutional Investors
53.80% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
INMB FAQ
What was Inmune Bio Inc’s price range in the past 12 months?
Inmune Bio Inc lowest stock price was $6.50 and its highest was $14.74 in the past 12 months.
What is Inmune Bio Inc’s market cap?
Currently, no data Available
When is Inmune Bio Inc’s upcoming earnings report date?
Inmune Bio Inc’s upcoming earnings report date is Aug 06, 2024 which is in 14 days.
How were Inmune Bio Inc’s earnings last quarter?
Inmune Bio Inc released its earnings results on May 09, 2024. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.535 by -$0.075.
Is Inmune Bio Inc overvalued?
According to Wall Street analysts Inmune Bio Inc’s price is currently Undervalued.
Does Inmune Bio Inc pay dividends?
Inmune Bio Inc does not currently pay dividends.
What is Inmune Bio Inc’s EPS estimate?
Inmune Bio Inc’s EPS estimate is -$0.63.
How many shares outstanding does Inmune Bio Inc have?
Inmune Bio Inc has 19,782,429 shares outstanding.
What happened to Inmune Bio Inc’s price movement after its last earnings report?
Inmune Bio Inc reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.535. Following the earnings report the stock price went down -6.964%.
Which hedge fund is a major shareholder of Inmune Bio Inc?
Currently, no hedge funds are holding shares in INMB
---
Inmune Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.67 (130.33% Upside)
$19.67 (130.33% Upside)
Blogger Sentiment
Bearish
INMB Sentiment 67%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $36.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.22%
12-Months-Change
Fundamentals
Return on Equity
-81.82%
Trailing 12-Months
Asset Growth
-36.69%
Trailing 12-Months
Company Description
Inmune Bio Inc
Inmune Bio, Inc. is a clinical stage biotechnology company, which develops immunotherapies that reprogram a patient's innate immune system to allow the immune system to fight cancer. Its products include INKMUNE and INB03. The company was founded by Mark Lowdell in September 2015 and is headquartered in La Jolla, CA.
---
INMB Earnings Call
Q1 2024
0:00 / 0:00
---
INMB Stock 12 Month Forecast
Average Price Target
$19.67
▲(130.33% Upside)
Technical Analysis
Best Analysts Covering INMB
1 Year
1 Year Success Rate
7/16 ratings generated profit
1 Year Average Return
-3.57%
reiterated a buy rating 23 days ago
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of -3.57% per trade.
---